Cargando…
Continuous infusional topotecan in advanced breast and non-small-cell lung cancer: no evidence of increased efficacy.
Two open, phase II studies were performed to evaluate the activity and toxicity of infusional topotecan in patients with advanced non-small-cell lung carcinoma (NSCLC) and advanced breast cancer who had not received previous chemotherapy for metastatic disease. Twenty-five patients with an ECOG perf...
Autores principales: | Mainwaring, P. N., Nicolson, M. C., Hickish, T., Penson, R., Joel, S., Slevin, M., Smith, I. E. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1997
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2228211/ https://www.ncbi.nlm.nih.gov/pubmed/9413954 |
Ejemplares similares
-
Weekly doxorubicin and continuous infusional 5-fluorouracil for advanced breast cancer.
por: Gabra, H., et al.
Publicado: (1996) -
Cyclophosphamide, methotrexate and infusional 5-fluorouracil (infusional CMF) in metastatic breast cancer.
por: O'Byrne, K. J., et al.
Publicado: (1998) -
Phase II study of continuous infusional 5-fluorouracil with epirubicin and carboplatin (instead of cisplatin) in patients with metastatic/locally advanced breast cancer (infusional ECarboF): a very active and well-tolerated outpatient regimen.
por: Bonnefoi, H., et al.
Publicado: (1996) -
Adjuvant chemotherapy for oesophagogastric cancer with epirubicin, cisplatin and infusional 5-fluorouracil (ECF): a Royal Marsden pilot study.
por: Bamias, A., et al.
Publicado: (1995) -
A phase I clinical trial of continual alternating etoposide and topotecan in refractory solid tumours
por: Penson, R T, et al.
Publicado: (2005)